Is Voquill profitable in 2026?

No. Voquill is a private, pre-seed/seed YC-backed startup (batch P26) with no disclosed revenue figures as of its May 20, 2026 Launch YC debut. It claims 25 pathologists at one unnamed F500 lab are using the tool, but no financials have been made public.

Could AI replace pathologists using Voquill?

Voquill's own product is an AI agent that already drafts sign-out-ready pathology reports from spoken findings, a task once done manually. As of May 2026 it claims ~20% time savings per pathologist in a 25-person pilot, but this is a vendor-claimed, unaudited figure.

Who are Voquill's biggest competitors?

General ambient-scribe giants Abridge and Microsoft Dragon Copilot (formerly Nuance DAX) plus LIS incumbents Clinisys/Sunquest, Epic Beaker, and Oracle Cerner PathNet. As of July 19, 2026, none had shipped a pathology-specific voice product, leaving Voquill's niche open but exposed.

Voquill is privately owned and backed by Y Combinator (batch P26). It was co-founded by CEO Michael Gibson, CTO Josiah Saunders, and COO Henry Habib, both Gibson and Saunders previously built AI pathology tools at Techcyte deployed at Mayo Clinic, Quest, and Labcorp.

How many customers does Voquill have?

As of its May 20, 2026 Launch YC post, Voquill claims 25 pathologists at one unnamed Fortune 500 lab use the tool, onboarded over the prior four weeks, saving roughly 20% of case-writing time daily. This is a vendor-claimed, self-reported figure with no named customer logo confirmed independently.

Is the Voquill pathology startup the same as the open-source Voquill dictation app?

There is naming overlap. An unrelated open-source dictation tool called Voquill (voquill.org, GitHub voquill/voquill, AGPLv3) was first published in July 2025 by Jack Brumley. A GitHub commit on April 10, 2026 titled 'update company name,' hosted under co-founder Josiah Saunders' account, suggests the YC startup absorbed or rebranded around this codebase, but the relationship is unconfirmed.

YC Spring 2026 · United States

Voquill

Voice AI scribe that drafts pathology reports and suggests CPT billing codes.

Protection under test

Assessed 27 July 2026 · Evidence as of 27 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 27 July 2026 · Checkable from H1 2027 · Every call on the record Checkpoint: Whether the F500 lab pilot expands to multi-site paid use with real retention data

The call

Voquill has a real early pathology foothold and founder access, but no shipped billing lock-in or multi-site proof yet, while bigger scribe and LIS players circle the same workflow.

Voquill is a software tool that lets pathologists dictate medical reports by voice and have them automatically written down and formatted. Right now, big companies like Abridge and Microsoft's Dragon Copilot do similar voice-to-text work for other doctors, and Epic (the hospital software giant) could easily add this feature to their pathology system, so Voquill is not hard to copy. The one thing that could save Voquill is if it becomes the system that pathologists use not just to write reports but also to handle billing and get paid, which would make hospitals and labs stick with it instead of switching.

Why

AI pressure: Microsoft Dragon Copilot, Abridge. These ambient scribes already dominate general clinical notes and could add a pathology mode, closing Voquill's window fast. Could AI do the core job? Only partly.

Bigger players: Epic Beaker, Clinisys/Sunquest, Oracle Cerner PathNet. These LIS vendors already sit inside every lab's workflow and could bolt on scribe features without Voquill's involvement. Could a giant copy it? Yes, easily.

What protects it. Founders' prior work at Techcyte gave them direct pathologist relationships at Mayo, Quest, and Labcorp before any pilot started.

What would change this call

Voquill pilot expands beyond the single F500 lab to additional paid sites within 12 months. Shows real multi-site traction rather than a single stalled pilot.
Abridge or Microsoft Dragon Copilot announce a pathology-specific product mode. Would signal horizontal scribe giants entering Voquill's niche and compressing its window.
Voquill ships deep integrations with Clinisys, Epic Beaker, or Cerner PathNet and discloses outcome-based pricing for CPT-coding/RCM features. Would show the billing lock-in moat is real rather than a bolt-on feature.

Key numbers

25+ pathologists onboarded in first 4 weeks (2026-05-20)
$8B+ CPT coding revenue labs leave uncaptured (2026-05-20)
Abridge valued at $5.3B after $300M raise (2025-06)

Named risks

Traction limited to one self-reported, unnamed 25-pathologist pilot with no independent verification. Severity: high
Well-funded Abridge or Microsoft Dragon Copilot could ship pathology mode and compress Voquill's window. Severity: high
Naming collision with unrelated open-source Voquill dictation tool causes market confusion. Severity: medium
No disclosed funding amount or revenue raises sustainability questions at pre-seed/seed stage. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Abridge	gaining on	Holds 2025 and 2026 Best in KLAS Ambient Speech award, $5.3B valuation as of June 2025
Microsoft Dragon Copilot	gaining on	Expanding ambient documentation with deep Epic/Cerner integration through 2026
Clinisys/Sunquest	contesting	LIS incumbent Voquill sits on top of; could build pathology voice features internally
Epic Beaker	contesting	Major LIS platform with distribution advantage if it enters pathology scribing

Questions people ask

Is Voquill profitable in 2026?: No. Voquill is a private, pre-seed/seed YC-backed startup (batch P26) with no disclosed revenue figures as of its May 20, 2026 Launch YC debut. It claims 25 pathologists at one unnamed F500 lab are using the tool, but no financials have been made public.
Could AI replace pathologists using Voquill?: Voquill's own product is an AI agent that already drafts sign-out-ready pathology reports from spoken findings, a task once done manually. As of May 2026 it claims ~20% time savings per pathologist in a 25-person pilot, but this is a vendor-claimed, unaudited figure.
Who are Voquill's biggest competitors?: General ambient-scribe giants Abridge and Microsoft Dragon Copilot (formerly Nuance DAX) plus LIS incumbents Clinisys/Sunquest, Epic Beaker, and Oracle Cerner PathNet. As of July 19, 2026, none had shipped a pathology-specific voice product, leaving Voquill's niche open but exposed.
Who owns Voquill?: Voquill is privately owned and backed by Y Combinator (batch P26). It was co-founded by CEO Michael Gibson, CTO Josiah Saunders, and COO Henry Habib, both Gibson and Saunders previously built AI pathology tools at Techcyte deployed at Mayo Clinic, Quest, and Labcorp.
How many customers does Voquill have?: As of its May 20, 2026 Launch YC post, Voquill claims 25 pathologists at one unnamed Fortune 500 lab use the tool, onboarded over the prior four weeks, saving roughly 20% of case-writing time daily. This is a vendor-claimed, self-reported figure with no named customer logo confirmed independently.
Is the Voquill pathology startup the same as the open-source Voquill dictation app?: There is naming overlap. An unrelated open-source dictation tool called Voquill (voquill.org, GitHub voquill/voquill, AGPLv3) was first published in July 2025 by Jack Brumley. A GitHub commit on April 10, 2026 titled 'update company name,' hosted under co-founder Josiah Saunders' account, suggests the YC startup absorbed or rebranded around this codebase, but the relationship is unconfirmed.

Timeline

2026-07-19Competitive brief notes no frontier lab has shipped a pathology-specific voice scribe yet
2026-07-02Third-party review flags user confusion between two products both named Voquill
2026-05-20Voquill publicly launches via Launch YC, claims 25-pathologist F500 pilot
2026-04-10GitHub repo shows 'update company name' commit tied to co-founder's account
2026-03-25README for open-source voice dictation codebase active on GitHub
2025-07Unrelated open-source Voquill dictation tool first published by Jack Brumley
2025-06Rival Abridge raises $300M Series E at $5.3B valuation

Revision history

27 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Ploy Standout Playabl.ai